1. Home
  2. GNPX vs RPGL Comparison

GNPX vs RPGL Comparison

Compare GNPX & RPGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

N/A

Current Price

$3.43

Market Cap

2.9M

Sector

Health Care

ML Signal

N/A

Logo Republic Power Group Limited Class A Ordinary Shares

RPGL

Republic Power Group Limited Class A Ordinary Shares

N/A

Current Price

$1.50

Market Cap

2.3M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
GNPX
RPGL
Founded
2009
2015
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
2.3M
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
GNPX
RPGL
Price
$3.43
$1.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
99.9K
562.6K
Earning Date
05-11-2026
05-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$21.40
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.21
52 Week High
$12.97
$13.06

Technical Indicators

Market Signals
Indicator
GNPX
RPGL
Relative Strength Index (RSI) 38.34 41.31
Support Level $1.88 $0.30
Resistance Level $3.62 $1.99
Average True Range (ATR) 0.22 0.39
MACD -0.06 -0.05
Stochastic Oscillator 4.09 17.67

Price Performance

Historical Comparison
GNPX
RPGL

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

About RPGL Republic Power Group Limited Class A Ordinary Shares

Republic Power Group Ltd is a provider of customized ERP software solutions, consulting and technical support services, and peripheral hardware to corporate clients and government agencies, including airports, cruise terminals, and technology, trading, and logistics companies. The Company operates from Singapore and has historically served clients in Singapore and Malaysia, offering ERP systems with functions such as accounting, procurement, workflow automation, real-time monitoring, and capabilities including planning, surveillance, and threat detection. The Company leverages artificial intelligence and modular algorithms to address complex operational requirements and integrates sensors, controls, and other hardware to enable IoT connectivity with autonomous or semiautonomous outcomes.

Share on Social Networks: